High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed
Launched by EASTERN COOPERATIVE ONCOLOGY GROUP · Mar 10, 2004
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Determine whether high-dose folic acid decreases global DNA hypomethylation, as well as other intermediary markers, in normal-appearing colonic epithelium of patients with colonic adenomas. II. Determine whether a decrease in global DNA hypomethylation and other intermediary markers can be induced safely and whether these effects persist after folic acid is discontinued in these patients. III. Confirm pilot data that indicates patients with adenomas have widespread DNA hypomethylation of the colorectal mucosa compared to controls. IV. Evaluate the effect of folic acid on the ...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Colonic adenoma(s) of at least 10 mm completely resected within 18 months prior to randomization or suspected adenomatous polyp(s) Colonoscopy with submission of at least 7 rectosigmoid biopsies required at entry No benign hyperplastic polyps or polyps less than 10 mm to be eligible for treatment No polyposis coli (i.e., more than 100 polyps in colon) No history of invasive colorectal cancer
- • PATIENT CHARACTERISTICS: Age: 21 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Platelet count greater than 100,000/mm3 Hemoglobin greater than 10 g/dL No untreated pernicious anemia Hepatic: Bilirubin less than 2 mg/dL ALT less than 2 times normal Alkaline phosphatase less than 2 times normal PT normal Renal: Not specified Gastrointestinal: No intestinal malabsorption No inflammatory bowel disease Other: No seizure within the past year No poor medical risk No other malignancy within past 5 years except basal cell cancer, superficial skin cancer, or carcinoma in situ of the cervix No vitamin B12 deficiency (less than 200 pg/mL) Not pregnant or nursing Fertile patients must use effective barrier contraception
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No concurrent methotrexate Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics No prior small bowel resection Other: No concurrent anticonvulsants No concurrent drugs that markedly interfere with folate absorption or metabolism (e.g., sulfasalazine and phenytoin) No concurrent vitamins during and for 2 years after beginning of study
About Eastern Cooperative Oncology Group
The Eastern Cooperative Oncology Group (ECOG) is a prominent clinical trial sponsor dedicated to advancing cancer research and improving patient outcomes through collaborative studies. Established in 1955, ECOG is a leading network of academic and community-based researchers who design and conduct multicenter clinical trials across various cancer types. With a focus on innovative treatment approaches, prevention strategies, and supportive care interventions, ECOG engages healthcare professionals and institutions nationwide. The group's commitment to rigorous scientific methodology and patient-centered care aims to enhance the understanding of cancer and foster the development of transformative therapies that benefit patients and the broader oncology community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
New York, New York, United States
Chicago, Illinois, United States
New York, New York, United States
Marshfield, Wisconsin, United States
Boston, Massachusetts, United States
Patients applied
Trial Officials
Joel Mason, MD
Study Chair
Tufts Medical Center Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials